Klertis (Sunitinib)

Sunitinib blocks multiple receptor tyrosine kinases such as VEGFR, PDGFR, KIT, and FLT3. By inhibiting these signaling pathways, it reduces new blood‑vessel formation (angiogenesis) and directly suppresses tumor cell proliferation, leading to slowed tumor progression across several cancer types.

The dosing regimen for Klertis is individualized and determined by the prescribing oncologist based on the specific cancer type, disease stage, patient weight, renal function, and tolerance. Healthcare professionals set the appropriate dose and schedule according to approved guidelines.

The safety of sunitinib in pregnancy and lactation has not been established. It is generally contraindicated for pregnant or nursing women because of potential fetal toxicity and unknown effects on breast‑fed infants. Effective contraception is recommended for women of child‑bearing potential during treatment.

To request Klertis, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Klertis (sunitinib) shares a similar mechanism with other multi‑targeted TKIs such as pazopanib and sorafenib, but differs in its specific kinase inhibition profile and approved indications. Clinical choice depends on tumor type, prior therapies, side‑effect tolerability, and physician experience. Comparative studies suggest comparable efficacy in renal cell carcinoma with distinct safety patterns.

Klertis tablets should be stored at temperatures below 25 °C, in the original blister pack, protected from moisture and direct sunlight. Do not refrigerate or freeze the product, and keep it out of reach of children.

Klertis is taken orally, usually once daily, with or without food as directed by the treating physician. Patients should swallow the tablet whole with water and follow the prescribed schedule, which may include treatment cycles with planned breaks to manage toxicity.

Serious adverse events linked to Klertis include cardiac dysfunction (e.g., reduced ejection fraction), severe hypertension, bleeding complications, thromboembolic events, hepatotoxicity, and profound neutropenia. Patients should be monitored regularly for these conditions, and treatment should be adjusted or discontinued if severe toxicity occurs.

Klertis is contraindicated in patients with known hypersensitivity to sunitinib or any tablet excipients. It should be avoided in individuals with uncontrolled hypertension, recent major cardiovascular events, severe hepatic impairment, or those who are pregnant or breastfeeding without appropriate risk‑benefit assessment.